China API Antidepressant Pimavanserin Tartrate Material Pimavanserin Tartrate Powder Pimavanserin Tartrate, Find details about China Pimavanserin Tartrate, Pimavanserin Tartrate Powder from API Antidepressant Pimavanserin Tartrate Material Pimavanserin Tartrate Powder Pimavanserin Tartrate
Product Name | Pimavanserin Tartrate |
CAS | 706782-28-7 |
Appearance | White crystalline powder |
MF | C54H74F2N6O10 |
MW | 1005.2 |
Purity | 99% |
Shelf Life | 2 Years |
The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.
Pimavanserin is the active pharmaceutical ingredient of Nuplazid®, which was approved by the FDA in 2016 for the treatment of hallucinations and delusions associated with psychosis in patients suffering from Parkinson's disease.